Exam 4 and Final Flashcards
Symptoms of ADHD
-inattention
-hyperactivity
-impulsivity
Presentation of ADHD in infancy
-irritability, fidgeting, crying
-difficulty feeding
-short periods of sleep/frequently interrupted sleep
Presentation of ADHD in preschool kids (3-5)
-excessive motor activity
-intense temper tantrums
Presentation of ADHD in school aged kids (6-11)
-difficulty academically
-combined inattention and hyperactive/impulsive
-combined oppositional defiant disorder, conduct disorder and aggression
Presentation of ADHD in adolescents (12-18)
-in attention and impulsivity
-significant functional impairement
-higher rates of delinquency, drug and alcohol use
-speeding/MVA»»in ADHD
Presentation of ADHD in adults
-inattention
-cognitive deficits
-impatient
-greater risk for unemployment, unstable relationships, hospitalizations, incarceration
Consequences of not treating someone with ADHD
-delays in language, motor or social development
-low frustration tolerance: irritability and mood lability
-impaired work/school performance
-social rejection in childhood and adolescence
-elevated incidence of interpersonal conflicts
-by early adulthood: increased risk of suicide attempts (due to impulsivity)
-increased prevalence of SUD
If a pt has a hx of substance abuse, what meds do you use?
-atomoxetine, viloxazine, Guanfacine ER, Clonidine ER, or bupropion
what tx can you give a pt who has Tourette’s Disorder?
dopamine antagonists or aloha-2 agonist
what tx can you give a pt who has bipolar disorder and/or severe aggression?
*always treat this first before adding adhd meds
-atypical antipsychotic, lithium or anticonvulsant
Stimulants facts
-1st line therapy in most cases
–> methylphenidate and amphetamines (amph are more potent:
-block dopamine and NE reuptake
-amphet increase catecholamine release
-inhibit monoamine oxidase
-lack of response to one class does not mean lack of response to another
Adverse effects of Stimulants
-psychiatric: psychosis/mania, aggression/violent behavior, severe anxiety/anxiety attacks –> dose reduction or cessation of stim and supportive tx
-cardiac: increased HR ~5 BPM, increased BP by ~2-7 mmHg (see a 20% increase risk in ED visits due to this)
-growth: ~1 cm decrease over 1-3 years, ~3 kg weight deficit in 1st year of use
Stimulants drug interactions
-addictive adverse effects when used in combo with another psychostimulants
-MAOIs should not be used within 14 days
-MPH can increase TCA concentrations
-antacids, PPIs, and H2RAs can increase absorption of MPH IR formulations and reduce release formulations
*antacids decrease excretion of AMP, PPIs can increase rate of absorption of AMP
-acidic agents can lower absorption of AMP
-CYP2D6 inhibitors can increase mixed AMP salt exposure
-concomitant use with alcohol can result in stimulants dumping
MPH LA pearls
-better for morning symptoms b/c it has a higher immediate release component
MPH PM pearls
-given at bedtime so starts working by the time the pt wakes up in the morning
Methylphenidate facts
**preferred product for use in children/adolescents
-time to peak can be delayed by high fat meals
-dosing: titrate weekly until clinical response observed, IR products dosed at least BID (preferred for pts < 16 kg), afternoon IR dose should not be given < 6 hours before bedtime
Methylphenidate pearls
-ramp effect: behavioral effects are proportional to the rate of MHP absorption into CNS
-tics can occur more often with transdermal patch
-BBW for skin reaction with transdermal patch (chemical leuko
MPH CD
-30% IR and 70% ER beads
-can open and put on applesauce
MPH LA
-50% IR and 50% ER beads
-can open and put on applesauce
-best for more severe morning symptoms compared to CD/MLR
MPH XR suspension
-requires VIGOROUS shaking for at least 10 seconds
-reconstituted and good for 4 months
MPH OROS
-swallow WHOLE, do not chew or crush
-will see shell in poop
-NOT good for ppl with GI strictures
MPH MLR
better for rebound afternoon symptoms due to larger ER ratio
MPH XR-ODT
-17.3 mg Qday- not dose eq. will have to titrate other meds from the start if switching
MPH PM
-no more than 5% of total drug absorbed in first 10 hours
-administer between 6:30-9:30 pm
MPH transdermal patch
-dose not eq to oral
-drug active for 3 hours after removal
-apply 2 hours prior to desired onset
-may be worn while swimming and/or bathing
-do not cut patches!
Dex-MPH XR
-50% IR and 50% ER beads
-peak serum 1.5 and 6.5 hrs after taken
-afternoon symptoms control not as good as OROS
Jornay PM (methylphenidate ER)
-1st layer: 10 hrs to dissolve
2nd layer dissolves throughout the day, 14 hours to drug peal
-20 mg Qday dose in the EVENING (6:30-9:30pm)
*if bedtime dose missed: skip and resume dosing at next bedtime
-
Lisdexamfetamine
-amphetamine
-designed for less abuse potential
Dyanavel XR (amphetamine ER solution)
-2.5 mg/mL (approved for > 6 y/o)
-side effects: epistaxis, upper abdominal pain, allergic rhinitis
Amphetamine XR-ODT/ER suspension (Adzenys)
-orally disintegrating tablet/liquid suspension
-approved for > 6 y/o
-do not chew, must be dissolved
Mydayis (mixed single entity amphetamine salts ER)
-> 13 y/o
-onset effect 1-2hrs, peak 16 hrs
**cannot convert mg to mg with other amphetamines
-triple time release beads within capsule to reduce medication wearing off
Amphetamine facts
-increase the release of DA and NE into the synapse from the pre-synaptic nerve terminal
-enhance release of NE in periphery
-high doses: stimulate serotonin release and acts as serotonin agonist
-high fat meals delay time to peak concentrations
Amphetamine pearls
**preferred stimulant in adults*
-titrate weekly until clinical response
-IR formulations given at least BID
CIs: not the preferred agent if pt has a hx of cardiovascular disease (HTN, arrhythmias, HF, recent MI)
Atomoxetine and Viloxazine ER for ADHD
-full benefit may not be seen for 6-8 weeks –> behavior may worsen initially (atomoxetine)
AEs: upset stomach, psych and cardio effects, greater fatigue, sedation and dizziness
**only FDA approved ADHD med with BBW for new-onset suicidality
Clonidine ER and Guanfacine ER for ADHD
-not as effective as stimulants for mono-therapy
-SEs: sedation/dizziness, hypotension, constipation, heart block
-clonidine commonly added adjunct to stimulants
-ER should not be taken with a high fat meal
Bupropion: 50-300mg/day for ADHD
-weak dopamine and NE reuptake inhibitor
-found beneficial in adolescents with ADHD and depression
AEs: less appetite suppression and weight loss compared to stimulants, seizures
TCAs: Imipramine, Desipramine, Nortriptlyine for ADHD
-up to 4 weeks to see max effects
-AEs: sedation/dizziness, constipation, heart block, weight gain, overdose toxicity & rapid heart beat
Lithium/ valproate or carbamazepine for ADHD
-effective for: aggression, explosive behavior, impulsivity
-childhood-onset bipolar disorder or combined ADHD-bipolar disorder
Antipsychotics for ADHD
-Chlorpromazine & haloperidol: hyperactivity, impulsivity, neg effects on learning, cog function and can cause EPS
-2nd gen: risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole –> severe aggression and risk of metabolic syndrome
Mechanisms of Pain
Nocicptive
-Stimulation: bradykinins, K+, prostaglandins, histamine, leukotrienes, serotonin, substance P
-Transmission: a-delta fibers: fast (sharp), localized (myelinated)
-preception
-modulation: endogenous opiate system, NMDA receptors decrease effects of opioids, serotonin, NE, GABA, neurotensin
Pain mechanisms and Responses of NP
NE and 5-HT neurons appear to provide: major descending modulation, inhibition for transmission of nociceptive information to the rostral levels of the CNS
-Endogenous analgesia center: PAG, noradernergic neurons –> inhibit at spinal cord (clonidine)
Neuropathic pain
-a clinical description which requires a demonstrable lesion or a disease that satisfies established neurological diagnostic criteria
Nervous System Damage
-increased nerve cell firing
-decreased inhibition of neuronal activity in central structures, usually due to deafferentation
-intact circuitry at the central level but a gain in response (sensitization) such that normal sensory input is amplified and sustained
Presentation/Assessment of neuropathic pain
1) Spontaneous transmission: continuous (burning, throbbing, aching, shooting, or intermittent (shooting, stabbing, or electric shock-like)
2) Hyperalgesia: increased pain from a stimulus that normally provokes pain
3) Allodynia: pain due to stimulus that does not normally provoke pain
TCAs for NP
–> nortrityline, desipramine, amitriptyline, imipramine
Advantages: most data, once daily dosing, concomitant insomnia, depression
Disadvantages: delayed onset, anti-ach, cardiotoxic
Dosing: trail at least 6-8 weeks with 2 weeks ! max dose
SNRIs/SSRIs for NP
-duloxetine and venlafaxine
advantages: duloxetine FDA approved in PDN, fibromyalgia, concomitant depression and better side effect profile
disadvantages: risk of SS +/- interacting meds, duloxetine CI in hepatic impairment and severe/ESRD
*drizalma Sprinkle: DR caps that you can sprinkle on food
Milnacipran (Savella)
-FDA approved for fibromyalgia
-well tolerated, can improve fatigue
-BID dosing, HTN
alpah-2 delta ligands MOA
Modulated hyper-excited neurons
-binds to presynaptic neurons at the alpha2-deltha subunit of voltage-gated calcium channels
-drug binding reduced calcium influx into presynaptic terminals
-decreased calcium influx reduces excessive release of excitatory NTs
Gabapentin for NP
-low incidence on DIs and ADRS, FDA approved PHN
-mild CNS depression, significant in toxicity
Renal things:
–> crcl > 30-59: 400-1400 mg/day BID
–> >15-29: 200-700 mg/day QD
–> = 15: 100-330 mg/day QD
Pregabalin for NP
-FDA indicated in PDN, PHN & fibromyalgia
-DEA schedule V- dependency, euphoria, mild CNS depression, significant in toxicity, renal insufficiency
Tramadol for NP
-Pros: moderate pain, less respiratory depression and abuse potential
*neuropathic pain: inhibits the reuptake of NE and serotonin in the CNS
-Cons: drug interactions, dizziness, GI, constipation and seizure risk
Tapentadol (Nucynta)
-indication: neuropathic pain associated with diabetic peripheral neuropathy
-DEA schedule II
-1st loading dose, may repeat once 1 hr after 1st dose
Capsaicin
-depletes and prevents accumulation of substance P in peripheral sensory neurons
-FDA approved
Qutenza 8% topical patch: pretreat with local anesthetic to treatment area, use up to 4 patched per application: patches should be applied for 60 mins and repeated no more frequently then every 3 months as needed
Lidocaine
Indications: PHN, topical anesthesia (skin, mucous membranes, stomatitis) –> if pt can pinpoint an area of pain
-we love this shit!
Painful Diabetic Neuropathy
1) damage to peripheral nerves: hyper-excitability, spontaneous impulses within axon & dorsal rot ganglion of these peripheral nerves
2) abnormal electrical connections
3) coupling of sympathetic and afferent neurons and abnormal release of substance P from A fiber
4) persistant nerve stimulation activates NMDA receptors located post synaptically in the dorsal horn
Painful Diabetic Neuropathy tx
-increase NE & 5HT in synaptic cleft: assumed to inc pain suppression induced by the descending inhibitory pathways
-TCAs, MOAIs, NMDA & sodium channel interference
-SNRIs: duloxetine and venlafaxine
-gabapentin and pregabalin
Post-herpic neuralgia (PHN)
-reactivation of Varicella-Zoster virus (shingles)
-distribution along dermatomes, ofetn causes PHN d/t sensory nerve damage = reduced neurite densities
PHN treatment
-TCAs
-gabapentin (Gralise ER & Enacarbil), pregabalin
-divaloproex Na
-tramadol
-opioids (oxycontin)
-lidocaine (FDA approved)
-capsaicin
Low Back Pain
-5th most common office visit reaons
-lumbosacral radiculopathy: most common
-inc pain = fear of movement
Management of low back pain
-APAP and NSAIDs 1st line for acute pain
-signs or symptoms of radiculopathy or spinal stenosis: consider referral for consideration of surgery or other invasive procedures
(acetaminophen can be used but does not have an anti inflammatory component)
Fibromyalgia
-enhanced sensitivity to stimuli: heat and cold
-pain is described as a constant dull ache in all 4 quadrants of the body
-often accompanied with fatigue and sleep disturbances and other comorbidities (fog)
Proposed causes of fibromyalgia
1) abnormalities in the neuroendocrine system, autonomic nervous system
2) genetic risk factors, associated with affective disorders
3) environmental triggers, physical, psychosocial stressors
4) central sensitization: blunted inhibitory response of the descending pain pathway & amplification of pain in the spinal cord spontaneous nerve activity
Fibromyalgia criteria
pt must satisfy at least 3:
1- widespread pain index >7 and symptoms severity scale score > 5 OR WPI of 4-6 and SSS score > 9
2- generalized pain, defined as pain in at least 4 of 5 regions, must be present. Jaw, chest and abdominal pain are not included
3- symptoms have been generally present for at least 3 months
4- a diagnosis of fibromyalgia is valid irrespective of other diagnosis. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses.
Fibromyalgia Treatment
-amitriptyline (at low dose)
-duloxetine
-milnacipran (useful in relieving the fog)
-tramadol
-pregabalin
-cyclobenzaprine
Katie is is taking 20mg QAM of lisdexamfetamine and has been successfully managed for the last 16 months. She cannot fall asleep at night. What is the best option?
Add Clonidine 0.1mg QHS {She is managed, no need to change}
Justin is a 13 yr old boy who recently started treating ADHD with 20 mg of amphetamine salts ER. His parents state that they feel there is more room for improvements. Which of the following would be the best recommendation?
○ Add cognitive behavioral therapy
○ Switch to methylphenidate 10mg
○ Add afternoon dose of lisdexamfetamine
○ Switch to atomoxetine
Add cognitive behavioral therapy {Pharmacological + Non-Pharmacological}
Gary is a 28 year old male with psychiatric disturbances and has been given the diagnosis of bipolar. He is having difficulty focusing, sitting still, and is unable to finish projects at work due to his racing thoughts. What is the best initial pharmacotherapy for him?
○ Atomoxetine
○ Valproic Acid
○ Methylphenidate
○ Guanfacine
Valproic Acid {Yes because bipolar is primary so you need to try that first}
-also only 1 environment- need 2
hich of the following statements is true regarding atomoxetine?
○ In head to head trials it was found to be less efficacious than stimulants
○ It is the only FDA approved ADHD medication with a BBW an increased risk of suicide
○ An adequate trial of therapy to determine efficacy is 4 weeks
○ Three times a day dosing can be used to improve tolerability
It is the only FDA approved ADHD medication with a BBW an increased risk of suicide
Addison is a 14 year old female with a recent diagnosis of ADHD who was trialed on dexmethylphenidate ER 10 mg QAM who was responding well during the school day but losing focus in the afternoon. Her past medical history includes asthma, ventricular septal defect, and tonsillectomy. What do you recommend? {Heart Defects = all stimulants caution sudden heart death}
○ Add dexmethylphenidate 5mg in the PM
○ Switch to amphetamine salts
○ Switch to guanfacine
○ Switch to atomoxetine
Add dexmethylphenidate 5mg in the PM
Ianisa 4 year old boy diagnosed with ADHD. The patient has exhausted all non-pharmacological interventions. They decided to initiate a pharmacological treatment at this time. What do you recommend?
Mixed amphetamine salts IR {Approved > 3 years}
Charlette is a 28 year old female with a longstanding history of SUD, She recently completed a 28 day
inpatient rehabilitation program and has been diagnosed with ADHD. She attends AN weekly. She was previously diagnosed with ADHD and has previously document success with stimulants in the past. She is re-enrolled in college and has already noted difficulty staying focused in class and completing her homework. What is least appropriate option for this patient?
○ Atomoxetine QHS
○ Methylphenidate OROS QD
○ Lisdexamfetamine QD
○ Methylphenidate IR BID
○ Methylphenidate IR BID {High Abuse potential}
SR is recently diagnosed with hypertriglyceridemia. His psychiatrist would like to prescribe a medication
that will not worsen his metabolic condition (i.e. hypertriglyceridemia). Which antipsychotic would most
likely contribute to the patient’s metabolic syndrome?
○ Chlorpromazine
○ Quetiapine
○ aripiprazole
○ thioridazine
Quetiapine